Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors

Nicola Abate, Manisha Chandalia, Rosa Di Paola, Daniel W. Foster, Scott M. Grundy, Vincenzo Trischitta

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Insulin resistance is pathogenic for type 2 diabetes and cardiovascular disease. Several inhibitors of insulin signaling have a role in human insulin resistance. The transmembrane glycoprotein ectonucleotide pyrophosphatase phosphodiesterase 1 (E-NPP1; also known as plasma cell membrane glycoprotein PC-1) interacts with the insulin receptor and inhibits subsequent signaling by decreasing its Β-subunit autophosphorylation. E-NPP1 is overexpressed in skeletal muscle, adipose tissue and cultured skin fibroblasts of insulin-resistant individuals who are not yet obese or diabetic, which indicates that excessive E-NPP1 expression is an early, intrinsic defect in human insulin resistance. Genetic studies also support a primary role of E-NPP1 in insulin resistance. Among other variants, a missense polymorphism, Lys121Gln, has been described.The Gln121 variant is a stronger inhibitor than Lys121 of insulin receptor function, and is associated with insulin resistance, type 2 diabetes and both cardiovascular and nephrovascular complications in diabetic patients. E-NPP1 is measurable in human serum, where it might represent a valuable biomarker of insulin resistance, but its relationship to tissue and systemic insulin resistance remains to be thoroughly elucidated. Understanding the mechanisms that regulate E-NPP1 expression and/or function might render this protein a new target for strategies to treat and prevent type 2 diabetes and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)694-701
Number of pages8
JournalNature Clinical Practice Endocrinology and Metabolism
Volume2
Issue number12
DOIs
StatePublished - Dec 27 2006
Externally publishedYes

Fingerprint

Insulin Receptor
Insulin Resistance
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Insulin
Diabetes Complications
ectonucleotide pyrophosphatase phosphodiesterase 1
Adipose Tissue
Glycoproteins
Skeletal Muscle
Fibroblasts
Biomarkers
Muscles
Skin
Serum
Proteins

Keywords

  • E-NPP1
  • Genetics
  • Insulin receptor
  • Insulin resistance
  • PC-1

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Mechanisms of disease : Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. / Abate, Nicola; Chandalia, Manisha; Di Paola, Rosa; Foster, Daniel W.; Grundy, Scott M.; Trischitta, Vincenzo.

In: Nature Clinical Practice Endocrinology and Metabolism, Vol. 2, No. 12, 27.12.2006, p. 694-701.

Research output: Contribution to journalArticle

Abate, Nicola ; Chandalia, Manisha ; Di Paola, Rosa ; Foster, Daniel W. ; Grundy, Scott M. ; Trischitta, Vincenzo. / Mechanisms of disease : Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. In: Nature Clinical Practice Endocrinology and Metabolism. 2006 ; Vol. 2, No. 12. pp. 694-701.
@article{5b22a03db1834a6dab1b760c54c91689,
title = "Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors",
abstract = "Insulin resistance is pathogenic for type 2 diabetes and cardiovascular disease. Several inhibitors of insulin signaling have a role in human insulin resistance. The transmembrane glycoprotein ectonucleotide pyrophosphatase phosphodiesterase 1 (E-NPP1; also known as plasma cell membrane glycoprotein PC-1) interacts with the insulin receptor and inhibits subsequent signaling by decreasing its Β-subunit autophosphorylation. E-NPP1 is overexpressed in skeletal muscle, adipose tissue and cultured skin fibroblasts of insulin-resistant individuals who are not yet obese or diabetic, which indicates that excessive E-NPP1 expression is an early, intrinsic defect in human insulin resistance. Genetic studies also support a primary role of E-NPP1 in insulin resistance. Among other variants, a missense polymorphism, Lys121Gln, has been described.The Gln121 variant is a stronger inhibitor than Lys121 of insulin receptor function, and is associated with insulin resistance, type 2 diabetes and both cardiovascular and nephrovascular complications in diabetic patients. E-NPP1 is measurable in human serum, where it might represent a valuable biomarker of insulin resistance, but its relationship to tissue and systemic insulin resistance remains to be thoroughly elucidated. Understanding the mechanisms that regulate E-NPP1 expression and/or function might render this protein a new target for strategies to treat and prevent type 2 diabetes and cardiovascular disease.",
keywords = "E-NPP1, Genetics, Insulin receptor, Insulin resistance, PC-1",
author = "Nicola Abate and Manisha Chandalia and {Di Paola}, Rosa and Foster, {Daniel W.} and Grundy, {Scott M.} and Vincenzo Trischitta",
year = "2006",
month = "12",
day = "27",
doi = "10.1038/ncpendmet0367",
language = "English (US)",
volume = "2",
pages = "694--701",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Mechanisms of disease

T2 - Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors

AU - Abate, Nicola

AU - Chandalia, Manisha

AU - Di Paola, Rosa

AU - Foster, Daniel W.

AU - Grundy, Scott M.

AU - Trischitta, Vincenzo

PY - 2006/12/27

Y1 - 2006/12/27

N2 - Insulin resistance is pathogenic for type 2 diabetes and cardiovascular disease. Several inhibitors of insulin signaling have a role in human insulin resistance. The transmembrane glycoprotein ectonucleotide pyrophosphatase phosphodiesterase 1 (E-NPP1; also known as plasma cell membrane glycoprotein PC-1) interacts with the insulin receptor and inhibits subsequent signaling by decreasing its Β-subunit autophosphorylation. E-NPP1 is overexpressed in skeletal muscle, adipose tissue and cultured skin fibroblasts of insulin-resistant individuals who are not yet obese or diabetic, which indicates that excessive E-NPP1 expression is an early, intrinsic defect in human insulin resistance. Genetic studies also support a primary role of E-NPP1 in insulin resistance. Among other variants, a missense polymorphism, Lys121Gln, has been described.The Gln121 variant is a stronger inhibitor than Lys121 of insulin receptor function, and is associated with insulin resistance, type 2 diabetes and both cardiovascular and nephrovascular complications in diabetic patients. E-NPP1 is measurable in human serum, where it might represent a valuable biomarker of insulin resistance, but its relationship to tissue and systemic insulin resistance remains to be thoroughly elucidated. Understanding the mechanisms that regulate E-NPP1 expression and/or function might render this protein a new target for strategies to treat and prevent type 2 diabetes and cardiovascular disease.

AB - Insulin resistance is pathogenic for type 2 diabetes and cardiovascular disease. Several inhibitors of insulin signaling have a role in human insulin resistance. The transmembrane glycoprotein ectonucleotide pyrophosphatase phosphodiesterase 1 (E-NPP1; also known as plasma cell membrane glycoprotein PC-1) interacts with the insulin receptor and inhibits subsequent signaling by decreasing its Β-subunit autophosphorylation. E-NPP1 is overexpressed in skeletal muscle, adipose tissue and cultured skin fibroblasts of insulin-resistant individuals who are not yet obese or diabetic, which indicates that excessive E-NPP1 expression is an early, intrinsic defect in human insulin resistance. Genetic studies also support a primary role of E-NPP1 in insulin resistance. Among other variants, a missense polymorphism, Lys121Gln, has been described.The Gln121 variant is a stronger inhibitor than Lys121 of insulin receptor function, and is associated with insulin resistance, type 2 diabetes and both cardiovascular and nephrovascular complications in diabetic patients. E-NPP1 is measurable in human serum, where it might represent a valuable biomarker of insulin resistance, but its relationship to tissue and systemic insulin resistance remains to be thoroughly elucidated. Understanding the mechanisms that regulate E-NPP1 expression and/or function might render this protein a new target for strategies to treat and prevent type 2 diabetes and cardiovascular disease.

KW - E-NPP1

KW - Genetics

KW - Insulin receptor

KW - Insulin resistance

KW - PC-1

UR - http://www.scopus.com/inward/record.url?scp=33845397703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845397703&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet0367

DO - 10.1038/ncpendmet0367

M3 - Article

C2 - 17143316

AN - SCOPUS:33845397703

VL - 2

SP - 694

EP - 701

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 12

ER -